Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.

Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H, Nojima T, Tanigawa R, Iizuka M, Iida Y, Loomba R. Aliment Pharmacol Ther. 2021 Sep 16. doi: 10.1111/apt.16596.

in cat NOT

Stay Connected

Would you like to receive updates from ProSciento?